Insider Transactions in Q4 2021 at Kala Pharmaceuticals, Inc. (KALA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2021
|
Mark S. Blumenkranz |
BUY
Grant, award, or other acquisition
|
Indirect |
5,183,355
+50.0%
|
-
|
|
Nov 15
2021
|
Mark S. Blumenkranz |
BUY
Grant, award, or other acquisition
|
Direct |
157,765
+50.0%
|
-
|
|
Nov 15
2021
|
Darius Kharabi CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
295,657
+50.0%
|
-
|
|
Oct 27
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
21,051
-9.33%
|
$21,051
$1.82 P/Share
|
|
Oct 26
2021
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
27,598
-9.32%
|
$27,598
$1.8 P/Share
|
|
Oct 26
2021
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
12,757
-4.19%
|
$12,757
$1.8 P/Share
|
|
Oct 26
2021
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
12,544
-9.32%
|
$12,544
$1.8 P/Share
|
|
Oct 26
2021
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,449
-6.49%
|
$9,449
$1.8 P/Share
|
|
Oct 26
2021
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
9,449
-7.49%
|
$9,449
$1.8 P/Share
|
|
Oct 26
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
9,449
-4.02%
|
$9,449
$1.8 P/Share
|